1. Home
  2. PVL vs SCLX Comparison

PVL vs SCLX Comparison

Compare PVL & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.81

Market Cap

60.1M

Sector

Energy

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.81

Market Cap

48.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVL
SCLX
Founded
2011
2011
Country
United States
United States
Employees
N/A
34
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.1M
48.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PVL
SCLX
Price
$1.81
$6.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
62.6K
109.6K
Earning Date
03-20-2026
04-10-2026
Dividend Yield
7.43%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$122.52
Revenue Next Year
N/A
$186.30
P/E Ratio
$26.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.61
$4.20
52 Week High
$2.04
$34.27

Technical Indicators

Market Signals
Indicator
PVL
SCLX
Relative Strength Index (RSI) 36.14 47.09
Support Level $1.75 $5.88
Resistance Level $1.91 $7.77
Average True Range (ATR) 0.05 0.92
MACD -0.01 -0.07
Stochastic Oscillator 8.82 39.53

Price Performance

Historical Comparison
PVL
SCLX

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: